Semax vs Selank: Two Research Neuropeptides Compared

A mechanism-level comparison of two short regulatory neuropeptides — one derived from ACTH, one from tuftsin — supplied strictly as laboratory reference standards.

Semax and Selank are frequently discussed together because they emerged from the same Russian school of regulatory-peptide chemistry and share a common design trick — yet they descend from entirely different parent molecules and engage different molecular systems. This article compares the two at the level of chemical identity, molecular target, and preclinical research context, so that a scientifically literate reader can see clearly where they converge and where they part ways.

Two peptides, one design philosophy

Both Semax and Selank are short, linear, synthetic heptapeptides developed around the Institute of Molecular Genetics of the Russian Academy of Sciences as part of a broader program to convert transient endogenous regulatory peptides into more metabolically stable research and reference compounds. Each was built by taking a biologically active fragment of a larger natural molecule and appending a C-terminal Pro-Gly-Pro (PGP) “glyproline” tail.

That PGP motif is the shared engineering feature. Proline-rich C-termini are comparatively resistant to cleavage by aminopeptidases and carboxypeptidases, so attaching Pro-Gly-Pro to a short bioactive fragment has been used to slow enzymatic degradation of the parent sequence in experimental systems. In other words, the two peptides rhyme structurally at their tail even though their functional “heads” are unrelated. Beyond that shared motif, the comparison is one of contrasts.

Semax: an ACTH(4-10)-derived neuropeptide

Sequence and origin

Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). Its “head” corresponds to the melanocortin-derived fragment of adrenocorticotropic hormone — the ACTH(4-7) core (Met-Glu-His-Phe) that lies within the classic ACTH(4-10) neurotropic fragment — extended by the stabilizing Pro-Gly-Pro tail. A defining chemical point is that Semax retains the neurotropic character associated with this ACTH fragment while being described as devoid of the corticotropic (steroidogenic) hormonal activity of full-length ACTH. It is, in effect, the behaviourally and neurochemically active portion of the melanocortin sequence decoupled from adrenal-hormone signalling.

Molecular targets and mechanism studied

The most heavily examined axis for Semax in preclinical work is the neurotrophin system. In a widely cited primary study, Semax bound specifically in rat basal forebrain tissue and was associated with increased levels of brain-derived neurotrophic factor (BDNF) protein, positioning it as an ACTH(4-10) analogue that intersects with neurotrophic signalling. Subsequent gene-expression work in rodent brain has examined how Semax influences the temporal dynamics of BDNF and nerve growth factor (NGF) transcripts, together with their tropomyosin-receptor-kinase (Trk) receptors, across the hippocampus and frontal cortex.

Mechanistically, then, the research framing for Semax centres on melanocortin-linked modulation of neurotrophic factors and their receptors, rather than on a single classical receptor. Additional preclinical literature has looked at its C-terminal PGP fragment as an active metabolite in its own right, and at Semax-associated changes in the expression of immune-response and inflammation-related genes in experimental cerebral-ischemia paradigms — again as molecular-level readouts in animal or tissue models.

Typical research context

In the preclinical literature, Semax is most often studied as a neuroprotection and neuroplasticity reference compound: models of experimental brain ischemia, neurotrophic gene-expression time courses, and rodent behavioural paradigms used to characterize melanocortin-analogue activity. These are all in-vitro or animal-model contexts examining mechanism, not statements about human outcomes.

Selank: a tuftsin-derived heptapeptide

Sequence and origin

Selank is the heptapeptide Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). Its “head” is tuftsin (Thr-Lys-Pro-Arg), an endogenous tetrapeptide derived from the CH2 (Fc) domain of the immunoglobulin-G heavy chain and classically described as a phagocytosis-stimulating, immunomodulatory factor. As with Semax, the natural fragment is extended by a Pro-Gly-Pro tail to yield a more stable synthetic analogue. Because tuftsin itself is an immune-derived peptide, Selank inherits a very different pharmacological lineage from Semax’s melanocortin origin.

Molecular targets and mechanism studied

Selank’s research profile spans two broad systems. The first is GABAergic neurotransmission. In vitro work in IMR-32 neuroblastoma cells reported that Selank — alongside GABA and a reference psychotropic — altered the expression of genes involved in GABAergic signalling, and complementary studies described Selank-associated changes in the expression of GABA-related genes in nervous tissue. This is the mechanistic basis for grouping Selank among peptides studied in anxiety-related behavioural research whose molecular targets are examined at the level of the GABA system and associated receptor-subunit transcripts.

The second axis is immunomodulation, a direct inheritance from tuftsin. Reviews of tuftsin and its analogs place Selank within a family of peptides studied for effects on cytokine and interferon expression and on innate immune signalling. Preclinical studies have additionally examined Selank in relation to monoaminergic (including serotonergic) gene expression, BDNF, and the metabolism of endogenous enkephalins — the last reflecting reports that tuftsin-type peptides can influence enzymatic degradation of enkephalin peptides. Taken together, the mechanistic framing for Selank is GABAergic and immunomodulatory, with monoamine- and neurotrophin-related readouts as secondary lines of inquiry.

Typical research context

Selank is commonly used as a reference compound in anxiety-related behavioural models in rodents, in cell-based assays of GABAergic gene expression, and in cytokine or immune-gene expression studies that trace its tuftsin heritage. Once again, these are preclinical and in-vitro contexts characterizing mechanism.

Side-by-side comparison

The table below summarizes the two peptides across the dimensions that actually distinguish them — parentage, molecular target, mechanism as studied, and research framing — rather than any notion of comparative effect in people, which is outside the scope of research-use material.

Where the two diverge — and where they rhyme

The temptation with any two neuroactive research peptides is to ask which is stronger or better. For research-use reference materials that question is not meaningful; there is no human endpoint to rank. The scientifically useful contrast is at the level of target and pathway.

• Different lineages. Semax descends from a stress-hormone (melanocortin) sequence but is studied for its neurotrophic, non-hormonal activity. Selank descends from an immune-derived peptide and carries an immunomodulatory signature into its neuroscience research profile.
• Different primary targets. The Semax literature is organized around BDNF/NGF and their Trk receptors; the Selank literature is organized around the GABA system and cytokine/immune signalling. A researcher choosing a reference compound for a neurotrophin-expression assay and one choosing a reference compound for a GABAergic gene-expression assay are reaching for different tools.
• Overlapping readouts. They are not wholly disjoint: both have been examined in relation to BDNF and to monoaminergic systems in preclinical models, which is part of why they appear side by side in the regulatory-peptide literature.
• Shared chemistry. The Pro-Gly-Pro tail is the one place the molecules genuinely rhyme — a stability strategy applied to two unrelated bioactive fragments.

Laboratory handling of both reference standards

As short proline-containing peptides, Semax and Selank are handled like typical lyophilized peptide reagents. General laboratory practice for reference standards of this type includes storing the lyophilized powder desiccated and cold (commonly at or below −20 °C), protected from light and moisture, and reconstituting only the working quantity in an appropriate laboratory solvent for the assay in question. Reconstituted aqueous solutions are generally kept refrigerated and used within a short window, with freeze–thaw cycling minimized to preserve peptide integrity. Both peptides are water-soluble, which simplifies preparation of stock solutions for in-vitro work. These notes describe reagent handling only and carry no implication of any use in or on humans or animals. Certificates of analysis and purity data should accompany reference-standard lots so that identity and concentration can be confirmed analytically before use.

Sourcing Semax and Selank for research in Canada

We supply both peptides as lyophilized laboratory reference standards for in-vitro and preclinical research. You can review specifications for Semax and Selank on their individual product pages, or browse the full catalog of research peptides. If you are new to procuring reference materials for a Canadian lab, our pillar guide to buying research peptides in Canada covers documentation, purity verification, and compliant handling in more depth. As with every compound we list, both Semax and Selank are offered exclusively for laboratory research and are not intended for human or animal use.

Selected research

1. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain Journal of Neurochemistry 2006. PMID 16635254
2. The effect of semax and its C-end peptide PGP on expression of the neurotrophins and their receptors in the rat brain during incomplete global ischemia Molekuliarnaia Biologiia (Moskva) 2011. PMID 22295573
3. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity Protein and Peptide Letters 2018. PMID 30255741
4. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells Frontiers in Pharmacology 2017. PMID 28293190
5. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission Frontiers in Pharmacology 2016. PMID 26924987
6. Tuftsin – Properties and Analogs Current Medicinal Chemistry 2017. PMID 28745220